Home › Compare › HOCXF vs ABBV
HOCXF yields 666.67% · ABBV yields 3.06%● Live data
📍 HOCXF pulled ahead of the other in Year 1
Combined, HOCXF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HOCXF + ABBV for your $10,000?
Promotora de Hoteles Norte 19, S.A.B. de C.V. develops, operates, and manages hotels in Mexico, Costa Rica, Colombia, and Chile. The company operates hotels under the City Junior by Marriott, City Express Suites by Marriott, City Express by Marriott, City Express Plus by Marriott, and City Centro by Marriott brands. It also provides marketing, technical, and administrative; real estate development; restaurant operation and catering; and IT, server maintenance, update, and equipment rental services, as well as software platforms and applications; and dashboards for hotel managers and operating teams. In addition, the company develops Front2Go, a property management system; hires personnel or third parties for the development of civil works; and invests in hospitality industry projects. It serves business travelers. The company was formerly known as Hoteles City Express, S.A.B. de C.V. and changed its name to Promotora de Hoteles Norte 19, S.A.B. de C.V. in April 2024. Promotora de Hoteles Norte 19, S.A.B. de C.V. was incorporated in 2002 and is headquartered in Mexico City, Mexico.
Full HOCXF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.